Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Articles in this issue
Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC
Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients
Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLC
Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLC
Lung Cancer Research Shows Distinct Genomic Differences in Younger Patients
Lung Cancer Incidence and Mortality Review Shows No Ethnic Differences in Women
NSCLC Study Shows Surprising Association Between Reduced Endocytic Activity and Metastases
Recent Videos
Related Content
